Curcumin treatment improves motor behavior in α-synuclein transgenic mice

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Spinelli, Kateri J ^a,b   Osterberg, Valerie R ^a,b   Meshul, Charles K ^b,c   Soumyanath, Amala ^b   Unni, Vivek K ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; CURCUMIN; NONSTEROID ANTIINFLAMMATORY AGENT; SNCA PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIET SUPPLEMENTATION; FEMALE; GAIT DISORDER; GENE OVEREXPRESSION; GLUCURONIDATION; HUMAN; HUMAN TISSUE; IN VIVO STUDY; LOCOMOTION; MALE; MOUSE; NERVE ENDING; NONHUMAN; PROTEIN AGGREGATION; PROTEIN PHOSPHORYLATION; ANIMAL; ANIMAL BEHAVIOR; DEMENTIA; DRUG EFFECTS; ENZYME IMMUNOASSAY; LEWY BODY; LIQUID CHROMATOGRAPHY; MOTOR ACTIVITY; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; TANDEM MASS SPECTROMETRY; TRANSGENIC MOUSE; WESTERN BLOTTING;

MUS; MUS MUSCULUS;

ALPHA-SYNUCLEIN; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BEHAVIOR, ANIMAL; BLOTTING, WESTERN; CHROMATOGRAPHY, LIQUID; CURCUMIN; DEMENTIA; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LEWY BODIES; MALE; MICE; MICE, TRANSGENIC; MOTOR ACTIVITY; PHOSPHORYLATION; TANDEM MASS SPECTROMETRY;

EID: 84934894524     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0128510     Document Type: Article

References (36)

1. Cole GM, Teter B, Frautschy SA (2007) Neuroprotective effects of curcumin. Adv Exp Med Biol 595:197-212. doi: 10.1007/978-0-387-46401-5-8 PMID: 17569212
2. Fan X, Zhang C, Liu D-B, Yan J, Liang H-P (2013) The clinical applications of curcumin: current state and the future. Curr Pharm Des 19:2011-2031. PMID: 23116310
3. Begum AN, Jones MR, Lim GP, Morihara T, Kim P, Heath DD, et al. (2008) Curcumin Structure-Function, Bioavailability, and Efficacy in Models of Neuroinflammation and Alzheimer's Disease. Journal of Pharmacology and Experimental Therapeutics 326:196-208. doi: 10.1124/jpet.108.137455 PMID: 18417733
4. Ma QL, Zuo X, Yang F, Ubeda OJ, Gant DJ, Alaverdyan M, et al. (2013) Curcumin Suppresses Soluble Tau Dimers and Corrects Molecular Chaperone, Synaptic, and Behavioral Deficits in Aged Human Tau Transgenic Mice. Journal of Biological Chemistry 288:4056-4065. doi: 10.1074/jbc. M112.393751 PMID: 23264626
5. Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, et al. (2005) Curcumin Inhibits Formation of Amyloid Beta Oligomers and Fibrils, Binds Plaques, and Reduces Amyloid in Vivo. Journal of Biological Chemistry 280:5892-5901. doi: 10.1074/jbc. M404751200 PMID: 15590663
6. Garcia-Alloza M, Borrelli LA, Rozkalne A, Hyman BT, Bacskai BJ (2007) Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model. J Neurochem 102:1095-1104. doi: 10.1111/j.1471-4159.2007.04613.x PMID: 17472706
7. Pan J, Li H, Ma J-F, Tan Y-Y, Xiao Q, Ding J-Q, et al. (2012) Curcumin inhibition of JNKs prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease through suppressing mitochondria dysfunction. Alzheimer's Research & Therapy 1:1-1. doi: 10.1186/2047-9158-1-16
8. Goedert M (2001) Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci 2:492-501. PMID: 11433374
9. Maries E, Dass B, Collier TJ, Kordower JH, Steece-Collier K (2003) The role of α-synuclein in Parkinson's disease: insights from animal models. Nat Rev Neurosci 4:727-738. doi: 10.1038/nrn1199 PMID: 12951565
10. Liu Z, Yu Y, Li X, Ross CA, Smith WW (2011) Curcumin protects against A53T alpha-synuclein-induced toxicity in a PC12 inducible cell model for Parkinsonism. Pharmacological Research 63:439-444. doi: 10.1016/j.phrs.2011.01.004 PMID: 21237271
11. Wang MS, Boddapati S, Emadi S, Sierks MR (2010) Curcumin reduces α-synuclein induced cytotoxicity in Parkinson's disease cell model. BMC Neurosci 11:57. doi: 10.1186/1471-2202-11-57 PMID: 20433710
12. Pandey N, Strider J, Nolan WC, Yan SX, Galvin JE (2008) Curcumin inhibits aggregation of α-synuclein. Acta Neuropathol 115:479-489. doi: 10.1007/s00401-007-0332-4 PMID: 18189141
13. Ahmad B, Lapidus LJ (2012) Curcumin Prevents Aggregation in α-Synuclein by Increasing Reconfiguration Rate. Journal of Biological Chemistry 287:9193-9199. doi: 10.1074/jbc. M111.325548 PMID: 22267729
14. Rockenstein E, Schwach G, Ingolic E, Adame A, Crews L, Mante M, et al. (2005) Lysosomal pathology associated with alpha-synuclein accumulation in transgenic models using an eGFP fusion protein. J Neurosci Res 80:247-259. doi: 10.1002/jnr.20446 PMID: 15765523
15. Spinelli KJ, Taylor JK, Osterberg VR, Churchill MJ, Pollock E, Moore C, et al. (2014) Presynaptic alphasynuclein aggregation in a mouse model of Parkinson's disease. J Neurosci 34:2037-2050. doi: 10. 1523/JNEUROSCI.2581-13.2014 PMID: 24501346
16. Yang K-Y, Lin L-C, Tseng T-Y, Wang S-C, Tsai T-H (2007) Oral bioavailability of curcumin in rat and the herbal analysis from Curcuma longa by LC-MS/MS. Journal of Chromatography B 853:183-189. doi: 10.1016/j.jchromb.2007.03.010 PMID: 17400527
17. Mohorko N, Repovs G, Popović M, Kovacs GG, Bresjanac M (2010) Curcumin labeling of neuronal fibrillar tau inclusions in human brain samples. Journal of Neuropathology and Experimental Neurology 69:405-414. doi: 10.1097/NEN.0b013e3181d709eb PMID: 20448485
18. Mutsuga M, Chambers JK, Uchida K, Tei M, Makibuchi T, Mizorogi T, et al. (2012) Binding of Curcumin to Senile Plaques and Cerebral Amyloid Angiopathy in the Aged Brain of Various Animals and to Neurofibrillary Tangles in Alzheimer's Brain. J Vet Med Sci 74:51-57. doi: 10.1292/jvms.11-0307 PMID: 21891973
19. Pan MH, Huang TM, Lin JK (1999) Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab Dispos 27:486-494. PMID: 10101144
20. Hampton TG, Amende I (2010) Treadmill gait analysis characterizes gait alterations in Parkinson's disease and amyotrophic lateral sclerosis mouse models. Journal of motor behavior 42:1-4. doi: 10. 1080/00222890903272025 PMID: 19906638
21. Amende I, Kale A, McCue S, Glazier S, Morgan JP, Hampton TG (2005) Gait dynamics in mouse models of Parkinson's disease and Huntington's disease. Journal of neuroengineering and rehabilitation 2:20. PMID: 16042805
22. Hausdorff JM, Cudkowicz ME, Firtion R, Wei JY, Goldberger AL (1998) Gait variability and basal ganglia disorders: stride-to-stride variations of gait cycle timing in Parkinson's disease and Huntington's disease. Mov Disord 13:428-437. PMID: 9613733
23. Blin O, Ferrandez AM, Serratrice G (1990) Quantitative analysis of gait in Parkinson patients: increased variability of stride length. Journal of the Neurological Sciences 98:91-97. PMID: 2230833
24. Roemmich RT, Nocera JR, Vallabhajosula S, Amano S, Naugle KM, Stegemöller EL, et al. (2012) Spatiotemporal variability during gait initiation in Parkinson's disease. Gait & posture 36:340-343.
25. Gispert S, Ricciardi F, Kurz A, Azizov M, Hoepken H-H, Becker D, et al. (2009) Parkinson Phenotype in Aged PINK1-Deficient Mice Is Accompanied by Progressive Mitochondrial Dysfunction in Absence of Neurodegeneration. PLoS ONE 4:e5777. doi: 10.1371/journal.pone.0005777.s010 PMID: 19492057
26. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB (2007) Bioavailability of Curcumin: Problems and Promises. Mol Pharmaceutics 4:807-818. doi: 10.1021/mp700113r PMID: 17999464
27. Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, Lee VM (2002) Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron 34:521-533. PMID: 12062037
28. Emmer KL, Waxman EA, Covy JP, Giasson BI (2011) E46K human alpha-synuclein transgenic mice develop Lewy-like and tau pathology associated with age-dependent, detrimental motor impairment. Journal of Biological Chemistry 286:35104-35118. doi: 10.1074/jbc. M111.247965 PMID: 21846727
29. Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS, et al. (2002) alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 4:160-164. doi: 10.1038/ncb748 PMID: 11813001
30. Anderson JP, Walker DE, Goldstein JM, de Laat R, Banducci K, Caccavello RJ, et al. (2006) Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem 281:29739-29752. doi: 10.1074/jbc. M600933200 PMID: 16847063
31. Oueslati A, Schneider BL, Aebischer P, Lashuel HA (2013) Polo-like kinase 2 regulates selective autophagic α-synuclein clearance and suppresses its toxicity in vivo. Proc Natl Acad Sci USA 110:E3945-E3954. doi: 10.1073/pnas.1309991110 PMID: 23983262
32. Ali RE, Rattan SI (2006) Curcumin's Biphasic Hormetic Response on Proteasome Activity and Heat-Shock Protein Synthesis in Human Keratinocytes. Annals of the New York Academy of Sciences 1067:394-399. doi: 10.1196/annals.1354.056 PMID: 16804017
33. Wang C, Zhang X, Teng Z, Zhang T, Li Y (2014) Downregulation of PI3K/Akt/mTOR signaling pathway in curcumin-induced autophagy in APP/PS1 double transgenic mice. European Journal of Pharmacology 740:312-320. doi: 10.1016/j.ejphar.2014.06.051 PMID: 25041840
34. Ebrahimi-Fakhari D, Cantuti-Castelvetri I, Fan Z, Rockenstein E, Masliah E, Hyman BT, et al. (2011) Distinct Roles In Vivo for the Ubiquitin-Proteasome System and the Autophagy-Lysosomal Pathway in the Degradation of α-Synuclein. J Neurosci 31:14508-14520. doi: 10.1523/JNEUROSCI.1560-11. 2011 PMID: 21994367
35. Nübling GS, Levin J, Bader B, Lorenzl S, Hillmer A, Högen T, et al. (2014) Modelling Ser129 phosphorylation inhibits membrane binding of pore-forming alpha-synuclein oligomers. PLoS ONE 9:e98906. doi: 10.1371/journal.pone.0098906 PMID: 24911099
36. Giasson BI, Duda JE, Murray IV, Chen Q, Souza JM, Hurtig HI, et al. (2000) Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 290:985-989. doi: 10.1126/science.290.5493.985 PMID: 11062131